Jose Carmona - Jan 31, 2022 Form 4 Insider Report for Rubius Therapeutics, Inc. (RUBY)

Role
Chief Financial Officer
Signature
/s/ Joanne M. Protano, Attorney-in-Fact
Stock symbol
RUBY
Transactions as of
Jan 31, 2022
Transactions value $
$0
Form type
4
Date filed
2/1/2022, 08:20 PM
Next filing
Jan 2, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RUBY Stock Option (Right to Buy) Award $0 +144K $0.00 144K Jan 31, 2022 Common Stock 144K $6.75 Direct F1
transaction RUBY Restricted Stock Units Award $0 +34.5K $0.00 34.5K Jan 31, 2022 Common Stock 34.5K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option shall vest on January 31, 2023, then in 12 equal quarterly installments thereafter.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3 The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023.